Lung cancer immune cell therapy study stopped early after just 2 patients

NCT ID NCT06519669

Terminated Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a treatment called GT201, which uses immune cells taken from a patient's own tumor to attack advanced lung cancer. It was designed for adults aged 18-70 with non-small cell or small cell lung cancer that had stopped responding to standard treatments. The study was terminated early after enrolling only 2 participants, so no clear conclusions about safety or effectiveness could be drawn.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT LUNG CANCER

Contacts and locations

Locations

Beijing GoBroad Hospital

Beijing, Beijing Municipality, 102200, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.